News

The company is also making preparations for a phase III registration program that is expected begin in the second half of this year. The double-blind, randomized, placebo-controlled and

The divestiture from Sanofi will fulfill the European Commission’s requirement related to the former’s deal with German drugmaker Boehringer Ingelheim. The deal includes Prontalgine, an analgesic for the treatment

 RB CEO Rakesh Kapoor said: “The acquisition of Mead Johnson is a significant step forward in RB’s journey as a leader in consumer health. With the Enfa family

The study was conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). In the trial, TRC105 combined with Avastin (bevacizumab) was compared to

Cinven has proposed to buy all the shares of Stada in a takeover offer, with each of them priced at €56. The offer from the other unnamed bidder has

Under an exclusive global licensing agreement, Seattle Genetics will develop, fund, manufacture and commercialize Immunomedics’ solid tumor therapy candidate, IMMU-132. Seattle will also take the responsibility to start

The stay order passed by the US Court of Appeals for the Federal Circuit will allow both the firms to appeal against the ruling of a federal judge in a

The clinical study will be conducted across approximately 15 centers in the United States. Jazz Pharmaceuticals research and development global head and development and chief medical officer Karen

GSD Ia is a rare, orphan genetic disease that results in excess accumulation of glycogen and lipids in liver tissue.  Data to date showed that treatment with VK2809